We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Cerus Corp (CERS) Common Stock USD0.001

Sell:$2.13 Buy:$2.43 Change: $0.005 (0.23%)
Market closed |  Prices as at close on 1 March 2024 | Switch to live prices |
Change: $0.005 (0.23%)
Market closed |  Prices as at close on 1 March 2024 | Switch to live prices |
Change: $0.005 (0.23%)
Market closed |  Prices as at close on 1 March 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Cerus Corporation is a biomedical products company. It is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives, such as platelets, plasma, red blood cells. Its product or product candidate under development include INTERCEPT Blood System-Platelets, INTERCEPT Blood System-Plasma, INTERCEPT Blood System-Red Blood Cells and INTERCEPT Blood System-Cryoprecipitation. The INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, red blood cell and IFC transfusion products.

Contact details

United States
+1 (925) 2886000

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$395.01 million
Shares in issue:
181.20 million
Health Care Supplies
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • William Greenman
    President, Chief Executive Officer, Director
  • Kevin Green
    Chief Financial Officer, Vice President - Finance
  • Vivek Jayaraman
    Chief Operating Officer
  • Alicia Goodman
    Chief Human Resource Officer
  • Carol Moore
    Senior Vice President - Regulatory Affairs, Quality and Clinical
  • Laurence Corash
    Chief Scientific Officer
  • Chrystal Menard
    Chief Legal Officer, General Counsel
  • Richard Benjamin
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.